Ocular Changes With Alpha-2 Receptor Agonist.

Glaucoma, Suspect Clinical Trial

Official title:

Ocular Changes After Selective Alpha-2 Receptor Agonist.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05670015
• Other study ID #: RC-2-2023
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: September 22, 2023

Study information

• Verified date: January 2023
• Source: Benha University
• Contact: Ahmed Abdelshafy, MD
• Phone: 01222328766
• Email: ahmad4lg[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

selective alpha-2 receptor agonists cause changes in intraocular pressure and pupillary size thus may affect patient quality of life.

Description:

In this research, we will analyze the effect of selective alpha-2 receptor agonists on the human eye and investigate ocular changes over 6 months after its topical use.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 22, 2023
• Est. primary completion date: August 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Glaucoma suspect cases.

• post-refractive surgery cases.

Exclusion Criteria:

• Cases with prostatic hyperplasia or diabetics that may alter the measurements of pupillary diameter.

• Cases with previous history of any retinal intervention or other drugs that may alter intraocular pressure measurements.

Related Conditions & MeSH terms

• Aberration, Corneal Wavefront
• Corneal Wavefront Aberration
• Glaucoma
• Glaucoma, Suspect
• Ocular Hypertension

Intervention

Drug:
• Low dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
• High dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.

Locations

Country	Name	City	State
Egypt	Ahmed Abdelshafy	Banha	QA

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intraocular pressure	Changes in intraocular pressure measured in mmHg by applanation tonometry	Baseline and 6 months after regular use of the topical eyedrops
Secondary	Pupillary diameter	Changes in the pupillary diameter measured in mm by handheld pupillometer	Baseline and 6 months after regular use of the topical eyedrops